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Background: The ideal treatment approach for colorectal cancer (CRC) with synchronous liver metastases
(SCRLM) remains debated. We performed a network meta-analysis (NMA) comparing the ‘bowel-ﬁrst’
approach (BFA), simultaneous resection (SIM), and the ‘liver-ﬁrst’ approach (LFA).
Methods: A systematic search of comparative studies in CRC with SCRLM was undertaken using the
Embase, PubMed, Web of Science, and CENTRAL databases. Outcome measures included postoperative
complications, 30- and 90-day mortality, chemotherapy use, treatment completion rate, 3- and 5-year
recurrence-free survival, and 3- and 5-year overall survival (OS). Pairwise and network meta-analysis
were performed to compare strategies. Heterogeneity was assessed using the Higgins I2 statistic.
Results: One prospective and 43 retrospective studies reporting on 10 848 patients were included. Pa-
tients undergoing the LFA were more likely to have rectal primaries and a higher metastatic load. The
SIM approach resulted in a higher risk of major morbidity and 30-day mortality. Compared to the BFA,
the LFA more frequently resulted in failure to complete treatment as planned (34% versus 6%). Pairwise
and network meta-analysis showed a similar 5-year OS between LFA and BFA and a more favorable 5-
year OS after SIM compared to LFA (odds ratio 0.25e0.90, p ¼ 0.02, I2 ¼ 0%), but not compared to BFA.
Conclusion: Despite a higher tumor load in LFA compared to BFA patients, survival was similar. A lower
rate of treatment completion was observed with LFA. Uncertainty remains substantial due to imprecise
estimates of treatment effects. In the absence of prospective trials, treatment of stage IV CRC patients
should be individually tailored.
© 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.Introduction
Colorectal cancer (CRC) is the second and third most frequent
cancer inwomen andmen, respectively [1]. At ﬁrst presentation, up
to 25% of patients present with synchronous liver metastases (stage
IV), whereas an estimated 50% will develop metachronous meta-
static disease [2e5]. The prognosis of stage IV CRC has steadilyivision of GI Surgery, Ghent
l Heymanslaan 10, B-9000,
.
on for Cancer Surgery, and the Eur
Surgical treatment of stage I
n Journal of Surgical Oncologimproved, with current 5-year overall survival (OS) rates ranging
from 40 to 60% [6,7].
Patients with synchronous colorectal liver metastases (SCRLM)
often require a complex and multimodal treatment. Different
therapeutic sequences have been proposed for the treatment of
stage IV CRC with SCRLM: the traditional bowel-ﬁrst approach
(BFA), the simultaneous approach (SIM), and the reversed or ‘liver-
ﬁrst’ approach (LFA). Each of these strategies is associated with
advantages and drawbacks (see Supplementary Table 1). The
‘reversed’ (liver ﬁrst) approach is based on the argument that
metastatic disease will ultimately deﬁne survival and should
therefore be treated ﬁrst [8]. Also, there is evidence suggesting thatopean Society of Surgical Oncology. All rights reserved.
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mor growth [9,10]. This may be explained by the pro-metastatic
effect of molecules released during wound healing, but also by
removing the primary tumor as a source of angiostatin, which in-
hibits metastatic outgrowth [11]. However, no consensus has yet
been reached on the optimal treatment sequence due to a lack of
randomized trials, and due to the rapidly changing systemic
treatment modalities.
Numerous small trials have compared different treatment ap-
proaches, and meta-analysis (MA) may generate a pooled estimate
of the observed effects with greater precision. Traditional MA
compares two different interventions, and this has been performed
to compare BFA with the SIM [12,13]. The recently introduced
technique of network meta-analysis (NMA), also termed indirect
meta-analysis or mixed treatment comparison, allows to estimate
metrics of all possible comparisons in the same model, simulta-
neously gathering direct and indirect evidence [14]. Kelly et al. [15]
published a NMA of all three treatment approaches in SCRLM in
2015, including 18 studies published until November 2013. In their
analysis, they concluded that there was no clear statistical surgical
outcome or survival advantage towards any of the three ap-
proaches. Since their work, additional studies have reported
outcome measures comparing LFA to BFA and/or SIM, possibly
allowing for a more robust and conclusive analysis [6,16e42]. Here,
we report an updated NMA and analyze the current evidence in the
treatment of stage IV CRC with SCRLM. We analyzed treatment
completion rate, postoperative morbidity, recurrence-free survival
(RFS), and overall survival (OS) of patients treated with either BFA,
LFA, or SIM. Other clinical, pathological, surgical, morbidity and
mortality-related variables were analyzed as well (see methods
2.4.).Materials and methods
Protocol and registration
A pair-wise MA and NMA was performed according to the
guidelines and recommendations from the preferred reporting
items for systematic reviews and meta-analysis checklist (PRISMA)
and its extension speciﬁcally developed to improve the reporting of
systematic reviews incorporating network meta-analyses [14,43].
This NMA and its protocol were registered at the PROSPERO In-
ternational prospective register of systematic reviews (PROSPERO
2017 CRD42017076127). Institutional review board or ethics com-
mittee approval was not required.Literature search
An electronic search strategy was designed in cooperation with
a biomedical librarian and was reﬁned for the Embase, PubMed,
Web of Science and the Cochrane Central Register of Controlled
Trials (CENTRAL) databases (see Appendix). Additional grey litera-
ture was searched using the Open Grey database (opengrey.eu),
which includes technical or research reports, doctoral dissertations,
conference papers, ofﬁcial publications, and other types of grey
literature. Congress abstracts were screened through the Embase
and Web of Science search strategies. In case of studies with
overlapping data reported by the same research group, the most
recent report was included. Also, we searched the clinicaltrials.gov
database for ongoing or completed relevant trials. The systematic
search of the literature was performed from date of inception until
January 31st, 2018. The literature search was completed on
February 1st, 2019.Please cite this article as: Ghiasloo M et al., Surgical treatment of stage I
review and network meta-analysis, European Journal of Surgical OncologSelection criteria
Eligible papers reported on a comparison of at least two
treatment approaches in stage IV colorectal cancer patients with
potentially resectable primary CRC and potentially resectable
synchronous liver metastasis. No language restrictions were
applied a priori. When necessary, authors of non-English language
studies were contacted to provide an English language summary
of their ﬁndings. Failure to establish contact or receive results in a
timely manner resulted in exclusion of these studies. We excluded
animal and in vitro studies, studies that did not report at least one
of the prespeciﬁed outcomes, non-comparative studies, and
studies using hybrid procedures or two-stage hepatectomies.
Also, studies that did not deﬁne the synchronous nature of LM
were excluded.
Studies were selected as follows: after pooling of all search re-
sults, titles and abstracts were independently reviewed by MG and
DP. In case of doubt, studies were selected for full text-screening.
Full-text screening was conducted independently by both authors
to identify studies fulﬁlling the inclusion criteria. In case of
disagreement, the senior authors (GB, RT and WC) were consulted
and a decision was taken in consensus. A ﬁnal list of included ar-
ticles was reviewed prior to data extraction.
Data extraction and outcomes of interest
Data extraction was performed independently by MG and DP
using an electronic form. The extracted data was double-checked
by a third author (MV). Disagreements were discussed with se-
nior authors until consensus was reached. The following outcomes
were extracted:
Primary outcomes: 3- and 5-year OS rate, 3- and 5-year RFS rate,
hepatic recurrence rate, 30- and 90-day operative mortality, and
postoperative overall and major complication rate (deﬁned as
Clavien-Dindo III or higher [44]). Studies reporting RFS and/or OS
from the date of diagnosis were excluded from the survival analysis,
but were included for all other analyses.
Additional outcomes: baseline and demographic variables (age,
gender, primary tumor location, anatomical distribution of LM,
deﬁnition of synchronous metastatic disease), treatment variables
(extent of surgery, systemic treatment administered), surgical
outcome (operative time, blood loss, transfusion requirements,
length of hospital stay), and treatment completion rate. Major
hepatectomy was deﬁned as removal of three or more Couinaud
segments. Treatment completion rate was deﬁned as the propor-
tion of patients which, when a non-simultaneous approach was
chosen, underwent both surgical treatments as planned.
Statistical analysis
The quality of included (non-randomized) studies was evalu-
ated using the Newcastle-Ottawa scale (NOS), which scores studies
on eight items, categorized into three groups: the selection of the
study groups, the comparability of the groups, and the ascertain-
ment of either the exposure or outcome of interest for case-control
or cohort studies respectively [45]. Scoring was performed inde-
pendently by MG and DP; any discrepancies were resolved in
consensus.
Pairwise MA and NMA were conducted using the Review
Manager software version 5.3 [46] and R software version 3.5.2,
respectively. Initial pairwise MA compared SIM versus BFA, LFA
versus BFA and SIM versus LFA. In the NMA, direct and indirect
analyses were performed, allowing simultaneous comparison of
the three treatment approaches. Here, BFA was the control
treatment e as all previous reports compared SIM or LFA cohortsV colorectal cancer with synchronous liver metastases: A systematic
y, https://doi.org/10.1016/j.ejso.2020.02.040
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whereas SIM and LFA were deﬁned as the intervention treat-
ments. Direct comparison of SIM versus BFA and LFA versus BFA
allowed indirect comparison between SIM and LFA. As a result, a
synthesis of data was created from a network of trials involving
multiple treatments, allowing to rank treatments according to
the observed outcome [47]. For dichotomous outcomes, the odds
ratio (OR) with its 95% conﬁdence interval (CI) was calculated.
For continuous variables, we calculated the mean difference
(MD) and the standardized mean difference (SMD). When no
mean or variance was reported, these were estimated from the
median, range and sample size [48]. Since survival rates were
rarely reported as lnHR (natural logarithm of the hazard ratio),
the numbers at risk and survival rates were used to calculate the
odds of survival. Heterogeneity between included studies was
assessed using the Higgins I2, and values > 30% were considered
to indicate potentially important heterogeneity between studies
[49]. When this occurred, both a ﬁxed and a random-effects
model were generated and compared. We reported the latter in
case of observable discrepancies. For I2 values < 30% only ﬁxed
models were calculated and reported.
Results
Search results
One prospective [50] and forty-three retrospective studies
[6,16e42,51e65] were included for analysis (Fig.1). All reports were
published between 1982 and 2016 (mean duration of included
studies 12.1 years). Review and selection results were nearly
identical between both authors, with the exception of one study,
where senior guidance was sought until consensus was obtained.
Appraisal was performed by means of the NOS, with the following
results: 7 studies scored 7stars on NOS scale, whereas 9 scored 8
stars and 28 scored 9 stars. Basic characteristics of the included
studies are outlined in Table 1.
Baseline characteristics
Seven out of 44 studies compared all three approaches, 28
compared BFA to SIM, and nine compared BFA to LFA. Twenty-one
studies included patients with extrahepatic disease, compared to
13 who exclusively reported on those without extrahepatic disease.
Eleven studies did not specify whether any extrahepatic metastases
were observed or not.
All 44 studies combined reported on 10 848 patients, with 7403
(68.24%), 2391 (22.04%) and 1054 (9.72%) patients in the BFA, SIM
and LFA cohorts, respectively. Across all studies, 60.32%, 56.03% and
63.75% of all patients were male in the BFA, SIM and LFA groups,
respectively.
Finally, more than 13 years after ﬁrst introducing the LFA by
Mentha et al. [66], still no consensus has been reached regarding
the deﬁnition of synchronous LM. Throughout the years many
different deﬁnitions have been used to describe synchronous liver
metastases. Most commonly synchronous metastases were re-
ported as LM diagnosed at the time of diagnosis of the primary
tumor [20,25,34,41,57,58], diagnosed preoperatively [22,28,30,
33,37,50,63], diagnosed before or during the primary tumor surgery
[17,24,29,32,39,42,52e55,61,62]. Others deﬁned synchronicity as
LM diagnosed one year before to three months after the diagnosis
of the primary tumor [38], discovered before or at the time of
diagnosis of the primary tumor [18], before initiation of treatment
[31], diagnosed within 30 [51] or 90 days of the diagnosis of the
primary tumor [6], diagnosed within 12 months after diagnosis of
the primary tumor and before any surgical intervention [21],Please cite this article as: Ghiasloo M et al., Surgical treatment of stage I
review and network meta-analysis, European Journal of Surgical Oncologdiagnosed before, during surgery of within 6 [64] or 12 months
after primary tumor resection [60]. Eleven studies failed to report
their deﬁnition of SCRLM.
Primary tumor distribution
Forty studies reported data on stage 4 colon and rectal cancer as a
single entity e i.e. they did not make a distinction between colon and
rectal cancer e whereas four studies only reported on rectal cancer
patients [6,31,32,62]. Two studies deﬁned rectal cancer as a tumor
located up to 15 cm from the anal verge, whereas one study deﬁned
rectal cancer as a tumor up to 20 cm from the anal verge. One study
did not provide a deﬁnition.
Signiﬁcant heterogeneity was observed between studies
reporting the origin of the primary tumor (i.e. colon or rectum)
(I2 ¼ 49.8%, p ¼ 0,0003). Colonic primaries were observed in 69.8%
of all patients in BFA, compared to 64.0% in SIM and 36.8% in LFA.
Hepatic disease distribution
The anatomical distribution of liver metastases was reported by
only 21 reports (5923 patients), and signiﬁcant heterogeneity was
observed in the distribution of the liver metastases (I2 ¼ 47.8%,
p ¼ 0.02).In comparison to BFA, SIM had signiﬁcantly less bilobar
metastatic disease [OR ¼ 0.65 (95%CI: 0.51e0.82)]. In contrast,
63.21% of the patients in the LFA had bilobar hepatic disease, compared
to 49.9% in the BFA. This difference was, however, not statistically
signiﬁcant [OR ¼ 1.11 (95%CI: 0.68e1.83)].
Treatment-related data
Hepatic resection
Rates of major hepatectomy were reported in 28 studies; with
three studies comparing all three approaches, 22 comparing BFA to
SIM, and three comparing BFA to LFA. Signiﬁcantly fewer patients
underwent major hepatectomy in the SIM cohort compared to BFA
[OR¼ 0.36 (95%CI: 0.29e0.46)]. No signiﬁcant difference was found
between the LFA compared to the BFA [OR ¼ 1.44 (95%CI:
0.93e2.22)]. The differences in major hepatectomy could however
be ascribed to the signiﬁcant heterogeneity (I2 ¼ 63.3%, p < 0.0001)
for all reported data.
Chemotherapy
Twelve studies reported details on preoperative chemotherapy.
Pairwise comparison showed LFA receiving more neoadjuvant
chemotherapy compared to BFA [OR ¼ 37.56 (95%CI: 5.74e245.60),
(p ¼ 0.0002)] (I2 ¼ 92.0%, p < 0.00001) and SIM [OR ¼ 0.16 (95%CI:
0.03e0.73), (p ¼ 0.02)] (I2 ¼ 62.0%, p ¼ 0.05). No difference was
observed between SIM and BFA [OR ¼ 1.26 (95%CI: 0.44e3.65),
(p¼ 0.67) (I2¼ 88.0%, p < 0.00001). The NMA conﬁrmed the results
from the pairwise analysis; signiﬁcantly more neoadjuvant
chemotherapy in LFA compared to BFA [OR ¼ 26.85 (95%CI:
6.71e107.42)], but no difference was observed between SIM and
BFA [OR ¼ 1.65 (95%CI: 0.51e5.31)]. There was however signiﬁcant
heterogeneity (I2 ¼ 88.6%, p < 0.0001).
Interval chemotherapy was reported by three studies. No dif-
ferences could be observed with pair-wise MA or NMA comparison
of LFA and BFA [OR ¼ 0.64 (95%CI: 0.36e1.14), (p ¼ 0.13)] (I2 ¼ 0%,
p ¼ 0.99). No comparisons were possible for SIM versus BFA or SIM
versus LFA.
Adjuvant chemotherapy details were reported by 10 studies.
Pairwise analysis showed no differences between SIM and BFA
[OR ¼ 1.21 (95%CI: 0.86e1.71), (p ¼ 0.28)] (I2 ¼ 53.0%, p ¼ 0.02). No
comparisonwas possible between LFA and BFA or between SIM and
LFA as only one study reported relevant data [50]. The NMA did notV colorectal cancer with synchronous liver metastases: A systematic
y, https://doi.org/10.1016/j.ejso.2020.02.040
Fig. 1. PRISMA ﬂow chart of search strategy results.
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0.50e5.50)] or between SIM and BFA [OR ¼ 1.21 (95%CI:
0.86e1.71)]. Heterogeneity was signiﬁcant at 53.2% (p ¼ 0.03).
Morbidity
Postoperative complications. Thirty-one studies reported the overall
postoperative complication rate (Fig. 2). Three studies compared all
three approaches, 26 compared BFA with SIM, and two studiesPlease cite this article as: Ghiasloo M et al., Surgical treatment of stage I
review and network meta-analysis, European Journal of Surgical Oncologcompared BFA with LFA. Pairwise comparison showed less post-
operative complication in SIM compared to BFA [OR ¼ 0.89 (95%CI:
0.78e1.01), (p ¼ 0.07)] (I2 ¼ 29.0%, p ¼ 0.07). In contrast, more
postoperative complications were observed in LFA compared to BFA
[OR ¼ 1.39 (95%CI: 0.98e1.96), (p ¼ 0.06)] (I2 ¼ 27.0%, p ¼ 0.24). No
difference was observedbetween SIM and LFA [OR ¼ 0.78 (95%CI:
0.49e1.55), (p¼ 0.64)] (I2 ¼ 9.0%, p¼ 0.33). Network MA observed a
borderline signiﬁcant greater number of postoperativeV colorectal cancer with synchronous liver metastases: A systematic
y, https://doi.org/10.1016/j.ejso.2020.02.040
Table 1
Demographic and study characteristics of the studies included in the network meta-analysis.
Study Journal Year Study period Completed treatment Completed BFA Completed SIM Completed LFA NOS
Abbott et al. [35] J Am Coll Surg 2012 1993e2010 144 84 60 NA 9
Andres et al. [36] Annals of Surg 2012 2000e2010 787 729 NA 58 8
Bigourdan et al. [37] Hep-Gastroenterol 2014 2000e2006 105 85 20 NA 9
Brouquet et al. [26] J Am Coll Surg 2010 1992e2009 142 72 43 27 8
Capussotti et al. [38] Ann Surg Oncol 2007 1985e2004 127 57 70 NA 9
Chua et al. [39] Dis colon rectum 2004 1996e1999 96 32 64 NA 9
Conrad et al. [6] Ann Surg Oncol 2017 1999e2014 210 134 37 39 9
De Haas et al. [40] Br J Surg 2010 1990e2006 228 173 55 NA 9
Esposito et al. [41] World J Surg 2018 2006e2013 653 587 NA 66 9
Fukami et al. [42] Surgery today 2016 2006e2013 63 22 41 NA 8
Inoue et al. [43] American Surgeon 2017 1995e2015 107 76 31 NA 7
Kaibori et al. [44] Dig Dis Sci 2010 1993e2007 74 42 32 NA 9
Le Souder et al. [45] J Surg Oncol 2018 2005e2016 155 127 28 NA 8
Li et al. [46] Chin J Cancer Res 2016 2009e2013 73 13 60 NA 9
Lim et al. [47] Ann Surg Oncol 2016 1989e2013 161 145 NA 16 9
Luo et al. [48] J Gastrointest Surg 2010 1994e2008 405 276 129 NA 7
Martin et al. [49] J Am Coll Surg 2009 1997e2008 230 160 70 NA 7
Mayo et al. [50] J Am Coll Surg 2012 1982e2011 1004 647 329 28 9
Moug et al. [51] Eur J Surg Oncol 2010 NR 64 32 32 NA 9
Nari et al. [52] Cirugia y Cirujanos 2018 1997e2013 212 149 63 NA 8
Okuno et al. [53] Surgery Today 2016 2006e2013 25 13 NA 12 9
Patrono et al. [54] Il Giornale di chirurgia 2014 1997e2012 104 60 46 NA 7
Reddy et al. [55] Ann Surg Oncol 2007 1985e2006 610 475 135 NA 8
Reding et al. [56] Swiss Med Weekly 2017 2000e2010 100 73 20 7 9
Sabbagh et al. [23] Int J of Surg 2015 2005e2013 27 17 7 3 9
Salvador-Roses et al. [24] Clin transl oncol 2017 2010e2015 30 15 NA 15 9
She et al. [57] ANZ J Surg 2015 1990e2008 116 88 28 NA 8
Silberhumer et al. [58] Surgery 2016 1984e2008 429 109 320 NA 9
Slupski et al. [59] Can J Surgery 2009 1997e2006 89 61 28 NA 7
Sturesson et al. [60] HPB 2017 2011e2015 140 91 NA 49 9
Tanaka et al. [61] Surgery 2004 1992e2003 76 37 39 NA 8
Tanaka et al. [62] Digestive Surgery 2015 1992e2012 30 28 NA 2 9
Thelen et al. [63] Int J Colorectal Dis 2007 1988e2005 219 179 40 NA 9
Turrini et al. [64] Eur J Surg Oncol 2007 1994e2005 119 62 57 NA 9
Valdimarsson et al. [65] HPB 2017 2008e2015 623 377 NA 246 9
Vallance et al. [66] Colorectal disease 2018 2010e2015 1838 1309 259 270 9
Van Der Pool et al. [25] Br J Surg 2010 2000e2007 57 29 8 20 9
Vassiliou et al. [67] World J Gastroenterol 2007 1996e2004 103 78 25 NA 8
Vogt et al. [68] World J Surgery 1991 1977e1987 36 17 19 NA 9
Wang et al. [69] Chin J Cancer 2008 1995e2005 83 46 37 NA 9
Weber et al. [70] Br J Surg 2003 1987e2000 97 62 35 NA 9
Welsh et al. [71] Br J Surg 2016 2004e2014 549 466 NA 82 9
Yan et al. [72] World J Surg 2007 NR 103 30 73 NA 8
Yoshidome et al. [73] J Gastrointestinal Surg 2008 1985e2006 137 21 116 NA 7
BFA, bowel-ﬁrst approach; LFA, liver-ﬁrst approach; NA, not applicable; NOS, Newcastle-Ottawa scale; NR, not reported; SIM, simultaneous approach.
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0.97e1.93)], but not between SIM and BFA [OR ¼ 0.91 (95%CI:
0.79e1.04)].
Only 14 studies reported the rate of major postoperative com-
plications (Clavien-Dindo grade 3 or higher). Pairwise analysis
showed more major postoperative complications in SIM compared
to LFA [OR¼ 3.45 (95%CI: 1.01e11.78), (p¼ 0.05)] (I2¼ 0%, p¼ 0.56).
No difference was observedbetween LFA and BFA [OR ¼ 0.79 (95%
CI: 0.29e2.15), (p¼ 0.65)] (I2¼ 46.0%, p¼ 0.11), or between SIM and
BFA [OR ¼ 1.21 (95%CI: 0.95e1.54), (p ¼ 0.12)] (I2 ¼ 0%, p ¼ 0.52).
The heterogeneity in the NMAwas low (I2¼ 7.9%, p¼ 0.73), with no
signiﬁcant difference between BFA and SIM [OR ¼ 1.23 (95%CI:
0.97e1.57)] or between BFA and LFA [OR¼ 1.15 (95%CI: 0.64e2.07)].
30- and 90-daymortality. The thirty-day mortality rate was reported
by eight studies. Pairwise MA showed no heterogeneity and no sig-
niﬁcant differences (p ¼ 0.35 for SIM versus BFA, p ¼ 0.39 for LFA
versus BFA, not calculable for SIM versus LFA as only 1 study
compared their 30-daymortality). These ﬁndings were conﬁrmed by
the NMA, as no heterogeneity was encountered (I2 ¼ 0%, p ¼ 0.41)
and no signiﬁcant differences were observed between LFA and BFA
[OR¼ 0.40 (95%CI: 0.05e3.33)] and between SIM and BFA [OR¼ 1.67
(95%CI: 0.67e4.18)].Please cite this article as: Ghiasloo M et al., Surgical treatment of stage I
review and network meta-analysis, European Journal of Surgical OncologOnly seven studies reported 90-day mortality. Similar to 30-day
mortality, no signiﬁcant differences were observed (p ¼ 0.22 for
SIM versus BFA, p ¼ 0.57 for LFA versus BFA, p ¼ 0.69 for SIM versus
LFA). The NMA conﬁrmed the results from pair-wise analysis, as no
signiﬁcant difference was observed between LFA and BFA [OR¼ 0.74
(95%CI: 0.21e2.64)] or between SIM and BFA [OR ¼ 1.39 (95%CI:
0.73e2.63)]. The heterogeneity was low (I2 ¼ 3.4%, p ¼ 0.92).Treatment completion. Limited data were reported regarding attri-
tion rates (Fig. 3). A total of eight studies reported on 1370 patients,
with 186 failing to complete the intended treatment. Of the pa-
tients failing, 57 (5.98%) were treatedwith the BFA,15 (18.98%) with
the SIM and 114 (33.73%) with the LFA. Pairwise MA showed a
higher attrition rate in LFA compared to BFA [OR ¼ 7.54 (95%CI:
2.72e20.96), (p ¼ 0.0001)] (I2 ¼ 76.0%, p ¼ 0.0002) and the SIM
[OR ¼ 0.25 (95%CI: 0.11e0.57), (p ¼ 0.0008)] (I2 ¼ 0%, p ¼ 0.39). No
difference was observed between SIM and BFA [OR ¼ 1.28 (95%CI:
0.63e2.59), (p¼ 0.49) (I2¼ 13.0%, p¼ 0.32). In the NMA, signiﬁcant
heterogeneity was observed (I2 ¼ 70.0%, p ¼ 0.0003), with a sig-
niﬁcant difference in attrition rate between LFA and BFA [OR¼ 6.76
(95%CI: 2.65e17.20)], but not between SIM and BFA [OR¼ 1.33 (95%
CI: 0.32e5.45)].V colorectal cancer with synchronous liver metastases: A systematic
y, https://doi.org/10.1016/j.ejso.2020.02.040
Fig. 2. Forest plots of pair-wise meta-analysis of the overall complications rate of the three surgical approaches. From top to bottom: LFA versus BFA, SIM versus BFA, BFA versus LFA.
M. Ghiasloo et al. / European Journal of Surgical Oncology xxx (xxxx) xxx6Survival
For the survival analyses, studies that calculated survival from
the date of diagnosis rather from the (last) surgical treatment were
excluded.Please cite this article as: Ghiasloo M et al., Surgical treatment of stage I
review and network meta-analysis, European Journal of Surgical OncologRecurrence free survival
Three-year and 5-year RFS were reported by 11 studies.
Compared to the BFA, lower 3-year RFS rates were observed with
SIM [OR¼ 1.72 (95%CI: 0.99e3.00), (p¼ 0.06)] (I2¼ 45.0%, p¼ 0.09)
and LFA [OR ¼ 1.52 (95%CI: 1.06e2.18), (p ¼ 0.02)] (I2 ¼ 0%,
p ¼ 0.60) (Fig. 4). No direct comparison was possible between SIMV colorectal cancer with synchronous liver metastases: A systematic
y, https://doi.org/10.1016/j.ejso.2020.02.040
Fig. 3. Forest plots of pair-wise meta-analysis of the attrition rate of the three surgical approaches. From top to bottom: LFA versus BFA, SIM versus BFA, BFA versus LFA.
Fig. 4. Forest plots of pair-wise meta-analysis of the 3-year recurrence-free survival rate of the three surgical approaches. From top to bottom: LFA versus BFA, SIM versus BFA.
M. Ghiasloo et al. / European Journal of Surgical Oncology xxx (xxxx) xxx 7
Please cite this article as: Ghiasloo M et al., Surgical treatment of stage IV colorectal cancer with synchronous liver metastases: A systematic
review and network meta-analysis, European Journal of Surgical Oncology, https://doi.org/10.1016/j.ejso.2020.02.040
M. Ghiasloo et al. / European Journal of Surgical Oncology xxx (xxxx) xxx8and LFA due to a lack of data. The NMA conﬁrmed the pairwise
comparisons and identiﬁed lower 3-year RFS rates for both LFA
conﬁrmed the pairwise analysis [OR ¼ 1.52 (95%CI: 1.06e2.18)]
andSIM [OR¼ 1.71 (95%CI: 1.15e2.55)] in comparison to the BFA.No
signiﬁcant heterogeneity was observed (I2 ¼ 28.8% p ¼ 0.18).
For the 5-year RFS rates, pairwise MA showed no signiﬁcant
differences between LFA and BFA [OR ¼ 0.57 (95%CI: 0.16e2.06),
(p ¼ 0.39)] (I2 ¼ 91.0%, p < 0.00001) and between SIM and BFA
[OR ¼ 1.07 (95%CI: 0.71e1.62), (p ¼ 0.74)] (I2 ¼ 31.0%, p ¼ 0.18). No
comparison was possible between SIM and LFA. The NMA
conﬁrmed the signiﬁcant heterogeneity rate (I2 ¼ 74.7%, p ¼ 0.51).
No signiﬁcant differences were observed between LFA and BFA
[OR ¼ 0.59 (95%CI: 0.25e1.38)], and between SIM and BFA
[OR ¼ 1.30 (95%CI: 0.68e2.47)].
Hepatic recurrence details were provided by 11 studies report-
ing on 2870 patients. Pairwise comparison showed no signiﬁcant
difference between LFA and BFA [OR ¼ 0.81 (95%CI: 0.53e1.24),
(p ¼ 0.33)] (I2 ¼ 0%, p ¼ 0.49) and between SIM and BFA [OR ¼ 1.12
(95%CI: 0.68e1.87), (p ¼ 0.65)] (I2 ¼ 79.0%, p < 0.0001). The NMA
showed no signiﬁcant differences between LFA and BFA [OR ¼ 0.89
(95%CI: 0.44e1.81)] and between SIM and BFA [OR ¼ 1.15 (95%CI:
0.72e1.83)]. There was, however, signiﬁcant heterogeneity
(I ¼ 72.3%, p ¼ 0.0003).
Overall survival
Twenty studies reported the 3-year OS rate. Pairwise compari-
son showed no signiﬁcant differences between LFA and BFA
[OR ¼ 1.21 (95%CI: 0.60e2.44), (p ¼ 0.89) (I2 ¼ 79.0%, p ¼ 0.002),
between SIM and BFA [OR ¼ 1.02 (95%CI: 0.81e1.28), (p ¼ 0.88)
(I2 ¼ 33.0%, p ¼ 0.09), or between SIM and LFA [OR ¼ 0.59 (95%CI:
0.05e7.55), (p ¼ 0.69) (I2 ¼ 95.0%, p < 0.0001). Signiﬁcant hetero-
geneity was observed in the NMA (I2 ¼ 54.1%, p ¼ 0.0016), which
did not show any signiﬁcant difference in 3-year OS between LFA
and BFA [OR ¼ 1.04 (95%CI: 0.63e1.72)] or between SIM and BFA
[OR ¼ 0.99 (95%CI: 0.76e1.31)].
Five-year OS was reported by 22 studies and no signiﬁcant
heterogeneity was observed in the pairwise analysis (Fig. 5). SIM
resulted in a signiﬁcantly better 5-year OS compared to LFA
[OR ¼ 0.47 (95%CI: 0.25e0.90), (p ¼ 0.02)] (I2 ¼ 0%, p ¼ 0.83).
However, no 5-year OS difference was observed between LFA and
BFA [OR¼ 0.88 (95%CI: 0.54e1.44), (p¼ 0.61)] (I2¼ 44.0%, p¼ 0.13)
or between SIM and BFA [OR ¼ 0.90 (95%CI: 0.75e1.08), (p ¼ 0.26)]
(I2 ¼ 14.0%, p ¼ 0.28). Non-signiﬁcant heterogeneity was observed
with the NMA (I2¼ 15.1%; p¼ 0.47), which showed a similar 5-year
OS survival rate between LFA and BFA [OR ¼ 0.98 (95%CI:
0.69e1.37)] and between SIM and BFA [OR ¼ 0.86 (95%CI:
0.71e1.04)].
Discussion
Advances in locoregional and systemic treatment modalities
have led to an impressive improvement of outcome in mCRC: over
30% of patients currently survive 5 years or longer [67]. In patients
presenting with synchronous liver metastases, the initial treatment
is usually determined by the extent, resectability, and symptomatic
burden of the primary tumor and its concomitant metastatic
component. The deﬁnition of ‘synchronous’ metastasis is not
standardized: an interval ranging from 0 to 12 months after diag-
nosis has been used in clinical trials and population registries.
When both the PT and the LM are easily resectable, several possible
treatment approaches can be considered. Simultaneous resection
offers the beneﬁt of requiring only one hospital stay, but is not
associated with considerable morbidity when either component
requires extensive surgery [68]. Reddy and colleagues showed
simultaneous colorectal resection with major hepatectomyPlease cite this article as: Ghiasloo M et al., Surgical treatment of stage I
review and network meta-analysis, European Journal of Surgical Oncologincreased mortality (8.3% versus 1.4%, p < 0.05) and severe
morbidity (36.1% versus 15.1%, p < 0.05) compared to combined
minor liver surgery [69]. The present NMA suggests that the
simultaneous approach results in a similar overall complication
rate, but in a higher risk of major complications in comparison to
the LFA e the cohort with the highest tumor burden in general.
In patients with asymptomatic primaries, the ‘liver ﬁrst’
approach has gained momentum over the past decades. This
approach is appealing in patients with borderline resectable liver
disease who are candidates fo r ‘conversion’ chemotherapy, and in
patients with rectal primaries in whom downstaging radiotherapy
or chemoradiation is required to facilitate an R0 resection. Our
analysis conﬁrms that, compared to the bowel ﬁrst approach, pa-
tients with the LFA are much more likely to receive upfront
chemotherapy. One of the arguments favoring the LFA is that sur-
gery of the primary tumor may accelerate growth of the metastatic
disease. In addition, surgery increases shedding of cancer cells into
the circulation, suppresses antitumor immunity, upregulates
adhesion molecules in target organs, and induces structural
changes in the target liver tissue [70]. Although evidence for these
mechanisms mainly stem from preclinical studies, it has been
clinically observed that resection of a primary CRC enhances
metabolic activity and tumor cell proliferation in coexisting LM
[71,72]. The present results suggest a higher rate of disease recur-
rence after LFA at three years, while OS is similar. However, any
comparison between LFA and BFA in the current analysis is
considerably biased, since important baseline characteristics such
as proportion of rectal cancer primaries, use of neoadjuvant
chemotherapy, LM volume, and extent of liver surgery were
signiﬁcantly different between both groups. In addition, the fact
that only six of the included studies reported that surgery of the
primary tumor and that of the LM were performed at the same
treating center suggests considerable referral bias. Nonetheless, the
more extensive metastatic disease in the LFA is subsequently more
prone to possible R1 resection margin(s), eventually increasing the
recurrence rate.
When a staged approach is decided upon, there is a risk that the
entire treatment schedule cannot be administered as planned.
Traditionally, this risk is perceived to be higher with the BFA, since
it is known that the risk of postoperative morbidity is much higher
in patients with stage IV colorectal cancer, compared to those with
earlier stage tumors [73]. Our results show, in fact, the opposite: the
proportion of patients who did not undergo the planned second
stage was 34% after the LFA versus 6% after the BFA. Again, this
difference is difﬁcult to interpret due to baseline imbalances be-
tween both groups, but may be explained by the higher metastatic
disease load in the LFA group, possibly leading to more patients
with hepatic recurrence and death from LM. Also, more patients in
the LFA group had rectal primaries, which may have responded
very well to (chemo)radiation and remained asymptomatic, obvi-
ating the need for subsequent mutilating surgery.
There are several limitations to the current NMA. First, all
studies but one are retrospective comparisons, which are
hampered by intrinsic sources of bias. Second, reporting of outcome
measures was often inconsistent, incomplete, or erroneous,
limiting the value of grouping these for the purpose of a meta-
analysis, and often resulting in signiﬁcant heterogeneity. Further-
more, stage IV colon and rectum cancer have been historically and
in fact unfairly reported as one group. Subsequently, subgroup
analysis distinguishing the origin of the primary tumor was prac-
tically impossible. Fortunately, recent publications have elected to
make a distinction based on the origin of the primary tumor and
should allow future meta-analysis to make this distinction
[6,31,32,62,74].
Unfortunately this study does not give indications on theV colorectal cancer with synchronous liver metastases: A systematic
y, https://doi.org/10.1016/j.ejso.2020.02.040
Fig. 5. Forest plots of pair-wise meta-analysis of the 5-year overall survival rate of the three surgical.
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proaches that, most likely, differs signiﬁcantly. Regardless, report-
ing of treatment-related data with appropriate regression analysis
should be encouraged. Finally, albeit meta-analysis is aimed to
compensate for small sample sizes, multicenter reporting should be
encouraged to increase the sample sizes and therefore, increase the
robustness of the performed analysis [75].Conclusions
In conclusion, the current NMA suggests that the LFA is
increasingly used in CRC patients with synchronous LM, speciﬁcally
in those with rectal cancer primaries and those with a high burdenPlease cite this article as: Ghiasloo M et al., Surgical treatment of stage I
review and network meta-analysis, European Journal of Surgical Oncologof metastatic disease. No signiﬁcant differences in hepatic recur-
rence or overall survival were found between the LFA and the BFA.
Simultaneous resection resulted in a higher rate of major compli-
cations and risk of death at 30 days.
Unfortunately, many difﬁculties were encountered while per-
forming this work. Mainly, the retrospective nature and incomplete
reporting have limited the robustness of this work. Furthermore,
considering stage IV colon and rectum cancer as one group pre-
vented further subgroup analysis. Regardless, until prospective
comparative trials are available, the treatment approach in patients
with stage IV CRC should be discussed in a multidisciplinary team
and tailored to the oncological, technical, and clinical characteris-
tics of each patient.V colorectal cancer with synchronous liver metastases: A systematic
y, https://doi.org/10.1016/j.ejso.2020.02.040
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